Multi-Omics Analysis Identified ADAM7 as a Biomarker and Therapeutic Target for End-Stage Renal Disease
Our findings identify ADAM7 as a potential biomarker and therapeutic target for ESRD-associated sarcopenia, offering insights for future intervention strategies.
Authors
- Xiaoqi Deng
- Lin Mei (ORCID: https://orcid.org/0000-0001-6503-5149)
- Yunfeng Lin (ORCID: https://orcid.org/0000-0003-1224-6561)
- Mengxi He
- Jinlan Wu
- Ma Li (ORCID: https://orcid.org/0000-0002-8948-0391)
- Yu Luo (ORCID: https://orcid.org/0000-0002-0711-2385)
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Zigong First People's Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Kidney & Blood Pressure Research
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1159/000550025
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00